Your genetics could make you more vulnerable to the side effects of the new class of Alzheimer’s drugs. Carrying two copies of the ApoE4…
Treatment with a powerful magnet is one of the newest experimental therapies being used to try to turn back the clock on Alzheimer’s disease….
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
Could a headset with flashing lights and sounds stimulate brain waves and treat Alzheimer’s? Cognito’s Phase 3 trial on such a device is trying…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
A Trump executive order has banned DEI initiatives across the federal government. Scientists say the move could undermine trial diversity and derail the quest…
Would you still participate in an Alzheimer’s clinical trial if you found out that because of your genetics, you were more vulnerable to serious…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
Bob Toia, 77, had a career in drug research, developing clinical trials for new drug entities at Proctor and Gamble. During those years, he…
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…
Athira Pharma’s experimental Alzheimer’s drug fosgonimeton hit a speedbump on its way toward FDA approval: The treatment failed to show a clinical benefit in…